| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1987PNAS...84..228H |
| P356 | DOI | 10.1073/PNAS.84.1.228 |
| P932 | PMC publication ID | 304176 |
| P698 | PubMed publication ID | 3491991 |
| P5875 | ResearchGate publication ID | 51256732 |
| P2093 | author name string | Nakajima K | |
| Hirano T | |||
| Taga T | |||
| Shimizu M | |||
| Yasukawa K | |||
| Sakiyama F | |||
| Tsunasawa S | |||
| Nakano N | |||
| Takatsuki F | |||
| Murashima A | |||
| P2860 | cites work | Cloning and expression of murine interleukin-1 cDNA in Escherichia coli | Q24300988 |
| Nucleotide sequence of human monocyte interleukin 1 precursor cDNA | Q24605740 | ||
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter | Q34161873 | ||
| Culture supernatants of a stimulated T-cell line have helper activity that acts synergistically with interleukin 2 in the response of B cells to antigen | Q35352553 | ||
| Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities | Q35597069 | ||
| B cell helper factors. I. Requirement for both interleukin 2 and another 40,000 mol wt factor | Q36345912 | ||
| Structure and expression of a cloned cDNA for human interleukin-2. | Q36603382 | ||
| Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). | Q37546825 | ||
| Novel B-cell maturation factor from spontaneously autoimmune viable motheaten mice | Q37577691 | ||
| B-cell-tropic interleukins in murine systemic lupus erythematosus (SLE) 1. | Q39370113 | ||
| Atrial myxomas: a review of clinical experience in 40 patients | Q39571522 | ||
| Regulation of B-Cell Growth and Differentiation by Soluble Factors | Q40119178 | ||
| T-cell-derived lymphokines that induce IgM and IgG secretion in activated murine B cells | Q40180194 | ||
| B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation | Q41826964 | ||
| Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. | Q42815506 | ||
| Immortalization of BGDF (BCGF II)- and BCDF-producing T cells by human T cell leukemia virus (HTLV) and characterization of human BGDF (BCGF II). | Q42818808 | ||
| Expression of human immune interferon cDNA in E. coli and monkey cells | Q48405865 | ||
| T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. | Q52828600 | ||
| Isocratic separation of PTH-amino acids at picomole level by reverse-phase HPLC in the presence of sodium dodecylsulfate. | Q53880737 | ||
| Role of γ-interferon in antibody-producing responses | Q56922589 | ||
| Replacement of T-cell function by a T-cell product | Q68996648 | ||
| Effect of B cell differentiation factor (BCDF) on biosynthesis and secretion of immunoglobulin molecules in human B cell lines | Q69936852 | ||
| Effect of recombinant IL 2 and gamma-IFN on proliferation and differentiation of human B cells | Q70077206 | ||
| More useful maleimide compounds for the conjugation of Fab' to horseradish peroxidase through thiol groups in the hinge | Q70648342 | ||
| A gas-liquid solid phase peptide and protein sequenator | Q70875325 | ||
| Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor- (TRF) like factor(s) | Q71590465 | ||
| Human helper T cell factor(s). IV. Demonstration of a human late-acting B cell differentiation factor acting on Staphylococcus aureus Cowan I-stimulated B cells | Q72818226 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| cell differentiation | Q210861 | ||
| autoantibody | Q785022 | ||
| P1104 | number of pages | 4 | |
| P304 | page(s) | 228-231 | |
| P577 | publication date | 1987-01-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production | |
| P478 | volume | 84 |
| Q67599183 | A case of Raynaud's disease with uterine cancer producing interleukin-6 |
| Q40663585 | A child who was feverish for 2 years |
| Q39877191 | A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression |
| Q38504890 | A greater variability in the 3' flanking region of the IL-6 gene in patients with systemic lupus erythematosus (SLE). |
| Q80697172 | A large atrial myxoma in a young woman |
| Q24310416 | A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family |
| Q36371158 | A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis |
| Q28646310 | Activation of interleukin-6 gene expression through the NF-kappa B transcription factor |
| Q45762183 | Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism |
| Q53805508 | An interleukin-6 transgene expressed in B lymphocyte lineage cells overcomes the T cell-dependent establishment of normal levels of switched immunoglobulin isotypes. |
| Q40963908 | Anti-cytokine therapy in rheumatoid arthritis |
| Q41609736 | Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo |
| Q37854935 | Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. |
| Q68551195 | Autoantibody production by severe combined immunodeficient mice reconstituted with synovial cells from rheumatoid arthritis patients |
| Q59077136 | Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas |
| Q39694827 | Autoimmune conditions induced by epithelial solid tumors |
| Q36354573 | B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes |
| Q39670145 | B-cell stimulatory factors (BSFs): molecular structure, biological function, and regulation of expression |
| Q40765834 | Castleman's Disease and Interleukin 6. |
| Q40576861 | Characteristics of cardiac myxoma with constitutional signs: a multicenter study in Japan. |
| Q71785360 | Clinical significance of elevated soluble interleukin‐6 receptor levels in the sera of patients with plasma cell dyscrasias |
| Q71716944 | Clinical, hematologic, and immunologic effects of interleukin-10 in humans |
| Q37679720 | Comparative evaluation of recombinant protein production in different biofactories: the green perspective |
| Q41733125 | Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene |
| Q34556797 | Constitutive production of interleukin-6 and immunologic features in cardiac myxomas |
| Q40889593 | Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation |
| Q58270969 | Cytokines in Rheumatoid Arthritis |
| Q33688127 | Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells |
| Q46153818 | Detection of interleukin-6 in human follicular fluid |
| Q73506622 | Disaccharide analysis of glycosaminoglycans synthesized by cardiac myxoma cells in tumor tissues and in cell culture |
| Q36353637 | Dysregulated expression of the T cell cytokine Eta-1 in CD4-8- lymphocytes during the development of murine autoimmune disease |
| Q34259037 | Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. |
| Q36816122 | Ectopic lymphokine gene expression in human peripheral blood lymphocytes in vivo |
| Q42093264 | Effect of anticancer drugs on the release of interleukin-6 in vitro |
| Q35783336 | Effectiveness of workplace rehabilitation interventions in the treatment of work-related upper extremity disorders: a systematic review |
| Q46024897 | Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology |
| Q67557643 | Elevated serum interleukin-6 levels in patients with acute hepatitis |
| Q70907154 | Endotoxin induced production of interleukin-6 is enhanced by vitamin E deficiency and reduced by black tea extract |
| Q52832954 | Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. |
| Q69049138 | Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis |
| Q28114782 | Expression of human mitochondrial NADP-dependent isocitrate dehydrogenase during lymphocyte activation |
| Q38203806 | Expression of the genes of interferons and other cytokines in normal and diseased tissues of man. |
| Q40681801 | Fever, arthralgias, skin lesions, and ischemic digits in a 59‐year‐old man |
| Q38336406 | From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis |
| Q24682989 | Functional murine interleukin 6 receptor with the intracisternal A particle gene product at its cytoplasmic domain. Its possible role in plasmacytomagenesis |
| Q41745145 | Growth autonomy and tumorigenicity of interleukin 6-dependent B cells transfected with interleukin 6 cDNA. |
| Q69230503 | High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production |
| Q68832695 | High-affinity binding sites for human 26-kDa protein (interleukin 6, B cell stimulatory factor-2, human hybridoma plasmacytoma growth factor, interferon-beta 2), different from those of type I interferon (alpha, beta), on lymphoblastoid cells |
| Q41615995 | Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors |
| Q73102242 | Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections |
| Q73276250 | IL-10 and IFN-gamma in Guillain-Barré syndrome. Network Members of the Swedish Epidemiological Study Group |
| Q34148654 | IL-6 in autoimmune disease and chronic inflammatory proliferative disease |
| Q34248105 | IL-6 in inflammation, immunity, and disease |
| Q41627715 | IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2 |
| Q47901598 | IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice |
| Q34288655 | IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation |
| Q37949664 | IL-6/IL-6 receptor system and its role in physiological and pathological conditions |
| Q34308376 | IgG1 plasmacytosis in interleukin 6 transgenic mice |
| Q47707811 | Immune dysfunction and the pathogenesis of AIDS-associated non-Hodgkin's lymphoma |
| Q68640968 | Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6 |
| Q38246202 | Immunopathogenesis of Sjogren's syndrome: "facts and fancy". |
| Q37181575 | Immunoregulators in the nervous system |
| Q37965754 | Immunotherapeutic implication of IL-6 blockade |
| Q34225642 | Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice |
| Q45124159 | In situ hybridization of IL-6 in rheumatoid arthritis |
| Q24515319 | Increased expression of interleukin 6 mRNA in cardiac myxomas |
| Q67924015 | Increased serum interleukin-6 in cardiac myxoma |
| Q44038799 | Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice |
| Q41417294 | Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane |
| Q34154676 | Inflammatory mediators increase surface expression of integrin ligands, adhesion to lymphocytes, and secretion of interleukin 6 in mouse Sertoli cells. |
| Q58181592 | Influence of IL-6 on Proliferation and Differentiation of Tonsillar Lymphocytes and Detection of IL-6 Producing Cells in Tonsil |
| Q47835958 | Innate immunity in cardiac myxomas and its pathological and clinical correlations. |
| Q40433201 | Inquiry into Murine and Human Lupus |
| Q40105940 | Interleukin (IL-6) Immunotherapy |
| Q41722189 | Interleukin 6 and its receptor: ten years later |
| Q36404163 | Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus |
| Q34734696 | Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir |
| Q34228814 | Interleukin 6 promotes murine lupus in NZB/NZW F1 mice |
| Q41874513 | Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes |
| Q53458293 | Interleukin-6 (IL-6) production in carcinoma of the cervix. |
| Q77399225 | Interleukin-6 and "complex" cardiac myxoma |
| Q35829806 | Interleukin-6 and insulin sensitivity: friend or foe? |
| Q73067831 | Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage hemopoietic progenitor cells |
| Q36559880 | Interleukin-6 and the acute phase response |
| Q41445780 | Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line |
| Q35816757 | Interleukin-6 immunoreactivity in human tumors |
| Q40850225 | Interleukin-6 in biology and medicine |
| Q37189514 | Interleukin-6 in clinical medicine |
| Q41210322 | Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? |
| Q90117830 | Interleukin-6 inhibition in the management of non-infectious uveitis and beyond |
| Q41702676 | Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis |
| Q47320913 | Interleukin-6 plasma levels and tumor size in cardiac myxoma |
| Q35993599 | Interleukin-6 serum level and monocyte production in head and neck cancer |
| Q36561156 | Interleukin-6: discovery of a pleiotropic cytokine |
| Q37826486 | Interleukins and tumor necrosis factor in inflammation |
| Q36816053 | Interleukins: Biological Properties and Therapeutic Potential |
| Q90468650 | Juvenile Granulosa Cell Tumor with Elevated Peripheral Interleukin-6 Level Shows Prolonged Fever and Delayed Puberty |
| Q41156462 | Lactic dehydrogenase virus infection prevents development of anti-nuclear antibody in (NZB x NZW)F1 mice; role of prostaglandin E2 and macrophage Ia antigen expression |
| Q57462089 | Macrophage depletion decreases IgG anti-DNA in cultures from (NZB · NZW)F1 spleen cells by eliminating the main source of IL-6 |
| Q77221418 | Malignant fibrous histiocytoma of the heart producing interleukin-6 |
| Q38718470 | Membrane Ig-mediated triggering of B cell tolerance and B cell clonal expansion: implications for rheumatoid factor production in rheumatoid synovitis |
| Q73836434 | Modulation of tumoricidal function in alveolar macrophages from lung cancer patients by interleukin-6 |
| Q35582135 | Neuronal cell cultures: a tool for investigations in developmental neurobiology |
| Q41076680 | Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control |
| Q35038021 | Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions |
| Q35096472 | Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. |
| Q35572368 | Pharmacodynamic monitoring of cyclosporin |
| Q33410688 | Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice |
| Q41755325 | Pretreatment of human vascular smooth muscle cells with interleukin-1 enhances interleukin-6 production and cell proliferation (action of IL-1 on vascular smooth muscle cells). |
| Q28256162 | Rapamycin inhibits proteasome activator expression and proteasome activity |
| Q34627008 | Rapid enhancement of beta 2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. |
| Q92924037 | Recent Advances in Electrochemical and Optical Biosensors Designed for Detection of Interleukin 6 |
| Q42938866 | Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression |
| Q38660546 | Regulation of colony-stimulating factor production by normal and leukemic human cells |
| Q41531127 | Regulation of interleukin-6 (IL-6) expression: evidence for a tissue-specific role of protein kinase C. |
| Q26998608 | Revisiting the 1986 molecular cloning of interleukin 6 |
| Q92104520 | Right atrial myxoma: a potential accelerator of pulmonary hypertension in the course of systemic sclerosis. The role of interleukin-6 |
| Q67882926 | Role of IL-6 in Human Antigen-Specific and Polyclonal IgA Responses |
| Q47872308 | Roles of protein phosphatase 2A in IL-6 signal transduction in Hep3B cells |
| Q46272739 | Serum cytokines in gestational trophoblastic diseases |
| Q70123615 | Significance of interleukin-6 in patients with inflammatory bowel disease |
| Q28246360 | Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism |
| Q69441237 | Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus |
| Q41349604 | Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene |
| Q34566660 | Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis |
| Q58746185 | The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against |
| Q39560514 | The interleukins in acquired disease |
| Q33581429 | The role of interleukin-6 in cases of cardiac myxoma. Clinical features, immunologic abnormalities, and a possible role in recurrence |
| Q33581541 | The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications |
| Q34430168 | The therapeutic potential of interleukin-6 hyperagonists and antagonists |
| Q38241714 | Therapeutic uses of anti-interleukin-6 receptor antibody |
| Q37803409 | Tocilizumab for the treatment of rheumatoid arthritis |
| Q35724900 | Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions |
| Q57278851 | Tumor Necrosis Factor-α Induces Interleukin-6 Production and Integrin Ligand Expression by Distinct Transduction Pathways |
| Q47256027 | Zinc as a Gatekeeper of Immune Function. |
Search more.